Diabetes mellitus and kidney disease in the elderly;Diabetes mellitus y enfermedad renal en el anciano

Nefrologia

Volumn 34, Issue 3, 2014, Pages 285-292

  Iglesias, Pedro ^a   Heras, Manuel ^b   Díez, Juan J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Diabetes mellitus; Elderly; Insulin; Oral antidiabetic agents; Renal disease

Indexed keywords

AGED; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMAN; RENAL INSUFFICIENCY, CHRONIC;

AGED; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84901369408     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Feb.12319     Document Type: Article

References (50)

1. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-53.
2. Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab 2005;31 Spec No 2:5S27-5S34.
3. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the u.s. Diabetes Care 2006;29:2415-9.
4. Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L. Chronic kidney disease and diabetes. Maturitas 2012;71:94-103.
5. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013;97:1-18.
6. Abbatecola AM, Paolisso G. Diabetes care targets in older persons. Diabetes Res Clin Pract 2009;86 Suppl 1:S35-40
7. Sinclair A, Morley JE, Rodriguez-Manas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502.
8. Kim KS, Kim SK, Sung KM, Cho YW, Park SW. Management of type 2 diabetes mellitus in older adults. Diabetes Metab J 2012;36:336-44.
9. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care 2012;35:2650-64.
10. Gomez Huelgas R, Diez-Espino J, Formiga F, Lafita Tejedor J, Rodriguez Manas L, Gonzalez-Sarmiento E, et al. Treatment of type 2 diabetes in the elderly. Med Clin (Barc) 2013;140:134.e1-134.e12.
11. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1:S11-66.
12. Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol 2011;119 Suppl 1:p1-5.
13. Musso CG, Macias Nunez JF, Oreopoulos DG. Physiological similarities and differences between renal aging and chronic renal disease. J Nephrol 2007;20:586-7.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;2 Suppl 1:S1-266.
15. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 1: Definition and classification of CKD. Kidney Int 2013:19-62.
16. Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly: pitfalls and errors. Nephron Clin Pract 2011;119 Suppl 1:c2-4.
17. Goldfarb-Rumyantzev AS, Rout P. Characteristics of elderly patients with diabetes and end-stage renal disease. Semin Dial 2010;23:185-90.
18. Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabeties Study. Diabetologia 2012;55:88-93.
19. Robles Raya MJ, Miralles Basseda R, Llorach Gaspar I, Cervera Alemany AM. Definición y objetivos de la especialidad de Geriatría. Tipología de ancianos y población diana. In: Sociedad Española de Geriatría y Gerontología, ed. Tratado de Geriatría para residentes. 2006. p. 25.
20. Lou Arnal LM, Campos Gutierrez B, Cuberes Izquierdo M, Gracia Garcia O, Turon Alcaine JM, Bielsa Garcia S, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus treated in primary care. Nefrologia 2010;30:552-6.
21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
22. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825-30.
23. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69.
24. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86.
25. Garg R, Williams ME. Diabetes management in the kidney patient. Med Clin North Am 2013;97:135-56.
26. Aires Neto P, Gomes HV, Campos M. Management of hyperglycemia in patients with chronic kidney disease. J Nephrol 2013;26:629-35.
27. Otero A, de Francisco A, Gayoso P, Garcia F. EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 2010;30:78-86.
28. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7.
29. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc 2013;61:1253-61.
30. Hasslacher C. Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91.
31. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006;154:613-21.
32. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (1995) 2011;39:7-21.
33. Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldanius PM. Individualised treatment targets for elderly patients with type 2 di-abetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382:409-16.
34. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1413-23.
35. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013;6:161-70.
36. Grunberger G. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin. Postgrad Med 2013;3:79-90.
37. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;8:648-58.
38. Schweizer A, Dejager S. Experience with vildagliptin in patients >75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 2013;4:257-67.
39. Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab 2013;17:413-21.
40. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm 2013;35:159-72.
41. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008;25:913-25.
42. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.
43. Franchin A, Corradin ML, Giantin V, Rossi F, Zanatta F, Attanasio F, et al. Diabetes in a geriatric ward: efficacy and safety of new insulin analogs in very old inpatients. Aging Clin Exp Res 2012;24(3 Suppl):17-9.
44. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26 Suppl 4:73-85.
45. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab 2008;10:811-23.
46. Pannarale G, Carbone R, Del Mastro G, Gallo C, Gattullo V, Natalicchio L, et al. The aging kidney: structural changes. J Nephrol 2010;23 Suppl 15:S37-40.
47. Esposito C, Dal Canton A. Functional changes in the aging kidney. J Nephrol 2010;23 Suppl 1:S41-5.
48. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis 2010;17:302-7.
49. Karam Z, Tuazon J. Anatomic and physiologic changes of the aging kidney. Clin Geriatr Med 2013;29:555-64.
50. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int 2012;82:270-7.